Sharing of clinical trial data: Benefits, risks, and uniform principles

Annals of Internal Medicine

Volumn 162, Issue 4, 2015, Pages 306-307

  Rosenblatt, Michael ^a   Jain, Sachin H ^b   Cahill, Matthew ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b CareMore Health System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); DRUG INDUSTRY; ETHNICITY; EUROPE; GENETIC TRAIT; HUMAN; INFORMED CONSENT; MEDICAL LITERATURE; NATIONAL HEALTH ORGANIZATION; NOTE; PATIENT CODING; POLITICAL SYSTEM; PRIORITY JOURNAL; RISK ASSESSMENT; SEXUAL ORIENTATION; SOCIAL MEDIA; UNITED STATES; ACCESS TO INFORMATION; CONFIDENTIALITY; INFORMATION DISSEMINATION; MASS MEDIUM; PUBLISHING;

ACCESS TO INFORMATION; CLINICAL TRIALS AS TOPIC; CONFIDENTIALITY; DRUG INDUSTRY; HUMANS; INFORMATION DISSEMINATION; MASS MEDIA; PUBLISHING; RISK ASSESSMENT;

EID: 84923273515     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M14-1299     Document Type: Note

References (10)

1. Bonini S, Eichler HG, Wathion N, Rasi G. Transparency and the European Medicines Agency-sharing of clinical trial data. N Engl J Med. 2014;371:2452-5. [PMID: 25539105] doi: 10.1056/NEJMp1409464
2. Pharmaceutical Research and Manufacturers of America; European Federation of Pharmaceutical Industries and Associations. Principles for Responsible Clinical Trial Data Sharing. 18 July 2013. Accessed at www.phrma.org/sites/default/files/pdf/PhRMAPrinciplesForResponsibleClinicalTrialDataSharing.pdf on 1 January 2015.
3. Institute of Medicine. Discussion Framework for Clinical Trial Data Sharing: Guiding Principles, Elements, and Activities. Washington, DC: National Academies Pr; 2014. Accessed at www.iom.edu/Activities/Research/SharingClinicalTrialData.aspx on 1 January 2015.
4. Doshi P, Goodman SN, Ioannidis JP. Raw data from clinical trials: within reach? Trends Pharmacol Sci. 2013;34:645-7. [PMID: 24295825] doi: 10.1016/j.tips.2013.10.006
5. National Institutes of Health. NIH Data Sharing Policy. Bethesda, MD: National Institutes of Health; 2007. Accessed at http://grants.nih.gov/grants/policy/data-sharing on 1 January 2015.
6. Prayle AP, Hurley MN, Smyth AR. Compliance with mandatory reporting of clinical trial results on ClinicalTrials.gov: cross sectional study. BMJ. 2012;344:d7373. [PMID: 22214756] doi: 10.1136/bmj.d7373
7. Cohen D. Rosiglitazone: what went wrong? BMJ. 2010;341:c4848. [PMID: 20819889] doi: 10.1136/bmj.c4848
8. Abramson JD, Rosenberg HG, Jewell N, Wright JM. Should people at low risk of cardiovascular disease take a statin? BMJ. 2013; 347:f6123. [PMID: 24149819] doi: 10.1136/bmj.f6123
9. Hiatt WR, Kaul S, Smith RJ. The cardiovascular safety of diabetes drugs-insights from the rosiglitazone experience. N Engl J Med.2013;369:1285-7. [PMID: 23992603] doi: 10.1056/NEJMp1309610
10. Godlee F. Adverse effects of statins [Editorial]. BMJ. 2014;348: g3306. [PMID: 25134141] doi: 10.1136/bmj.g3306